| Prev Close | 22.10 |
| Open | 22.06 |
| Day Low/High | 21.29 / 22.14 |
| 52 Wk Low/High | 28.82 / 46.24 |
| Volume | 825.02K |
| Avg Volume | 1.77M |
| Exchange | NASDAQ |
| Shares Outstanding | 69.13M |
| Market Cap | 1.49B |
| EPS | 1.80 |
| P/E Ratio | 12.61 |
| Div & Yield | N.A. (N.A) |
Latest News
MYGN: Insiders vs. Shorts
The most recent short interest data was recently released for the 07/29/2016 settlement date, and Myriad Genetics, Inc. is one of the most shorted stocks of the Russell 3000, based on 21.79 "days to cover" versus the median component at 6.42.
Bearish Bets: A Defense Firm, an Oil Driller and Other Stocks That Look Good Short
AIR, DO, MLNX, HALL and MYGN were all recently downgraded by TheStreet's Quant Ratings.
Will Myriad Genetics (MYGN) Stock React to Price Target Cut at Jefferies?
Jefferies lowered its price target to $20 on Myriad Genetics (MYGN) stock this morning saying that 'hereditary cancer cracks are emerging.'
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AOSL, ARES, BREW, CHTR, FSIC, GBDC, IPAR, LUK, LUNA, NRCIA, ODP, OLED, PIP, STRL, VIPS Downgrades: BCRH, CBNK, DF, HALL, MDVN, MYGN, NMR, NYRT, SGU, TCRD, TEO Initiations: APPF, GLPI, SPNE, TDOC Read on to get TheStreet Quant Ratings' detailed report:
5 Big Stocks to Add to Your Buy List -- Plus 2 to Avoid
Here's a technical look at how to trade some of the most active stocks on the market right now.
Why I Feel Bearish About the Market
I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.
Myriad Genetics (MYGN) Stock Tumbles on Q4 Earnings Miss, Guidance
Following Tuesday's market close, Myriad Genetics (MYGN) reported lower-than-expected earnings for the 2016 fourth quarter and lowered guidance for the year.
Analysts' Actions -- Coach, SunPower, Wayfair, Yelp and More
Here are Wednesday's top research calls, including upgrades for Coach and Yelp, and downgrades for SunPower and Wayfair.
Myriad Genetics Signs Definitive Agreement To Acquire Assurex Health
Allows Entry Into Attractive High-Growth Neuroscience Market
Analysts' Actions -- Dow, Ford, Harley, Target and More
Here are Friday's top research calls, including downgrades for Harley-Davidson and Ford, an upgrade for Dow Chemical and new coverage on Target.
Myriad's MyChoice® HRD Test Successfully Identifies Patients That Meet Primary Endpoint In TESARO's Pivotal Phase 3 Ovarian Cancer Study With Niraparib
myChoice HRD Increases Eligible Patients by Approximately Twofold
Crescendo Bioscience Announces That New Data On Vectra® DA Will Be Presented At The European League Against Rheumatism 17th Annual Congress
Three Studies Demonstrate the Utility of Vectra DA to Help Predict Treatment Response and Remission in Patients with RA
Myriad MyRisk® Hereditary Cancer Test Demonstrates The Magnitude Of Breast And Ovarian Cancer Risk In Nearly 100,000 Patients
New Studies at the 2016 ASCO Annual Meeting Demonstrate a 2- to 40-Fold Increased Risk
Myriad Will Present Three New Hereditary Cancer Studies At The ASCO Annual Meeting
New Data Highlight the Power of the Myriad myRisk® Hereditary Cancer Test To Identify More Mutation Carriers Without Increased Risk of Distress
Myriad Acquires Sividon Diagnostics
Strengthens Market Leading Oncology Product Portfolio with Breast Cancer Prognostic Test EndoPredict®
Myriad To Present New Research At The 2016 ASCO Annual Meeting
Data Demonstrate Expanded Utility of the Myriad myRisk® Hereditary Cancer Test
Myriad To Present Three New Studies At The AUA Annual Meeting
New Data Highlight the Power of the Prolaris® Test to Predict 10-Year Oncologic Outcomes in Patients with Low-Risk Localized Prostate Cancer
